{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:01:04Z","timestamp":1775131264911,"version":"3.50.1"},"reference-count":13,"publisher":"University of Tokushima Faculty of Medicine","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2152\/jmi.64.296","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T18:55:20Z","timestamp":1506452120000},"page":"296-298","source":"Crossref","is-referenced-by-count":5,"title":["Levetiracetam improves symptoms of multiple chemical sensitivity: Case report"],"prefix":"10.2152","volume":"64","author":[{"given":"Yosuke","family":"Kakisaka","sequence":"first","affiliation":[{"name":"Department of Epileptology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Epileptology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Epileptology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kitazawa","sequence":"additional","affiliation":[{"name":"Department of Epileptology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Nakasato","sequence":"additional","affiliation":[{"name":"Department of Epileptology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"925","reference":[{"key":"1","unstructured":"1. Multiple chemical sensitivity: a 1999 consensus [Editorial]. Arch Environ Health 54: 147-149, 1999"},{"key":"2","unstructured":"2. Miller CS, Prihoda TJ: The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health 15: 370-385, 1999"},{"key":"3","unstructured":"3. Genuis SJ: Chemical sensitivity: pathophysiology or pathopsychology? Clin Ther 35: 572-577, 2013"},{"key":"4","unstructured":"4. Staudenmayer H, Binkley KE, Leznoff A, Phillips S: Idiopathic environmental intolerance: Part 2: A causation analysis applying Bradford Hill's criteria to the psychogenic theory. Toxicol Rev 22: 247-261, 2003"},{"key":"5","unstructured":"5. Genuis SJ: Sensitivity-related illness: the escalating pandemic of allergy, food intolerance and chemical sensitivity. Sci Total Environ 408: 6047-6061, 2010"},{"key":"6","unstructured":"6. Lynch B, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101: 9861-9866, 2004"},{"key":"7","unstructured":"7. Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM: A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol 106: 1227-1239, 2011"},{"key":"8","unstructured":"8. Oliveira AA, Almeida JP, Freitas RM, Nascimento VS, Aguiar LM, J\u00fanior HV, Fonseca FN, Viana GS, Sousa FC, Fonteles MM: Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol 27: 395-406, 2007"},{"key":"9","unstructured":"9. Marini H, Costa C, Passaniti M, Esposito M, Campo GM, Ientile R, Adamo EB, Marini R, Calabresi P, Altavilla D, Minutoli L, Pisani F, Squadrito F: Levetiracetam protects against kainic acid-induced toxicity. Life Sci 74: 1253-1264, 2004"},{"key":"10","unstructured":"10. Al-Shorbagy MY, El Sayeh BM, Abdallah DM: Additional antiepileptic mechanisms of levetiracetam in lithium-pilocarpine treated rats. PLoS One 8: e76735, 2013"},{"key":"11","unstructured":"11. Pall ML: NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. FASEB J 16: 1407-1417, 2002"},{"key":"12","unstructured":"12. Lee JJ, Song HS, Hwang YH, Lee HW, Suh CK, Park SP: Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. J Clin Neurol 7: 128-136, 2011"},{"key":"13","unstructured":"13. Fayed N, Andres E, Rojas G, Moreno S, Serrano-Blanco A, Roca M, Garcia-Campayo J: Brain dysfunction in fibromyalgia and somatization disorder using proton magnetic resonance spectroscopy: a controlled study. Acta Psychiatr Scand 126: 115-125, 2012"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/64\/3.4\/64_296\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T03:19:10Z","timestamp":1506741550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/64\/3.4\/64_296\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":13,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.64.296","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}